Alerta

Screening culture medium as well as preparation method and application thereof

Resumen de: CN120464710A

The invention discloses a screening culture medium and a preparation method and application thereof, the screening culture medium comprises a basic culture medium and additives, and the additives comprise amphotericin B, vancomycin, ox bile salt, sodium deoxycholate and No.3 bile salt. According to the screening culture medium provided by the invention, a special infectious microbe inhibitor is added on the basis of a trisaccharide iron culture medium, so that most gram-negative enterobacter, staphylococcus aureus and part of fungi except salmonella enteritis subspecies and shigella cannot grow; the interference of the infectious microbes on the detection of the salmonella enteritis subspecies and the shigella is avoided, so that the fluorescent probe can be applied to the detection of the salmonella enteritis subspecies and the shigella in a clinical anus swab, and the sensitivity of color development is improved.

Application of rutin as salmonella type III secretion system inhibitor

Resumen de: CN120459124A

The invention discloses a novel application of rutin in preparation of a salmonella type III secretion system (T3SS) inhibitor. By constructing a salmonella mouse infection model, the rutin is proved to be capable of remarkably improving the survival rate of infected mice, reducing the bacterial load of liver and spleen target organs and effectively relieving the tissue damage of intestinal tracts, livers and spleens. In-vitro tests show that rutin does not affect the growth of bacteria, and the mechanism of the rutin playing a protection role is that the expression of a salmonella T3SS virulence factor is specifically inhibited, so that the pathogenicity of salmonella is weakened. The invention discloses a potential application of rutin as a salmonella T3SS inhibitor, and provides a theoretical basis for development of related anti-infective drugs.

Application of cordate houttuynia extract as salmonella type III secretion system inhibitor

Resumen de: CN120459191A

The invention provides a novel application of a cordate houttuynia extract as a salmonella type III secretion system (T3SS) inhibitor. Through construction of a mouse infection model and in-vitro experiments, the extract is proved to be capable of remarkably reducing the bacterial load of infected mouse liver and spleen tissues, relieving tissue pathological damage and reducing inflammatory cell infiltration. Mechanism research shows that the Houttuynia cordata extract can down-regulate the expression of T3SS key virulence protein SipA in a dose-dependent manner, interfere the function of a secretion system, and further block the secretion and expression of virulence factors. The potential application of the herba houttuyniae extract in the aspect of resisting salmonella toxicity is disclosed for the first time, and a development strategy and a technical basis of a T3SS inhibitor derived from a natural product are provided.

3 Optimization of a novel type of trivalent inactivated Salmonella bacterial vaccine for the prevention of avian typhoid and Salmonella food poisoning in poultry

Resumen de: KR20250121896A

본 발명은 사람에서 세균성 식중독을 일으키는 주요 원인균인 S. Enteritidis 및 S. Typhimurium, 그리고 가금에서 폐사를 일으키는 가금티푸스 원인균인 S. Gallinarum에 대한 산란계에서의 효과적인 살모넬라균 감염 예방을 위한 최적의 예방 프로그램 확립을 위한 발병을 수행하였다. 약독화 생균 백신만을 접종한 경우와 3가 살모넬라 불활화 사균체 백신만을 단독 접종한 산란계 모두에서 폐사는 발생하지 않았지만, 내부 장기 및 맹장 그리고 총 배설강 등에서 도전감염 균주가 분리되었다. 하지만 시판 백신인 약독화 생균 백신인 SG9R을 1차로 피하 접종한 후, 3가 살모넬라 불활화 사균체 (살모넬라 엔터라이티디스, 살모넬라 타이피뮤리움, 살모넬라 갈리나룸 불활화 사균체) 백신으로 추가로 근육 접종할 경우에는 내부 장기 및 맹장과 총배설강 등지에서 도전감염 균주가 분리되지 않았다. 이를 통해 약독화 생균 백신 및 3가 살모넬라 불활화 사균체 백신을 단독으로 접종한 경우보다 약독화 생균 백신 접종 후, 3가 살모넬라 불활화 사균체 백신을 추가로 접종할 경우 산란계에서 주요 살모넬라균을 효과적으로 예방할 수 있음이 확인하였다.

Tail Spike ProteinTSP Composition for rapid detection of E. coli using engineered bacteriophage Tail Spike ProteinTSP and method for producing thereof

Resumen de: KR20250121172A

E. coli O157:H7을 감염하는 두 종의 박테리오파지 SFP10과 PhiV10로부터 얻은 tail spike protein(TSP)를 엔지니어링 하여 항체를 사용하지 않고도 식품 내 E. coli O157:H7균을 신속하게 검출할 수 있는 방법 및 이의 방법으로 제작된 재조합 단백질이다.

Bacillus subtilis capable of strongly inhibiting clostridium perfringens

Resumen de: CN120464522A

The invention discloses bacillus subtilis capable of strongly inhibiting clostridium perfringens and relates to the technical field of microorganisms, the bacillus subtilis is preserved in China General Microbiological Culture Collection Center on November 25, 2024, the preservation number is CGMCC No.32783, the bacillus subtilis is classified and named as bacillus subtilis, and the bacillus subtilis is preserved in the China General Microbiological Culture Collection Center on November 25, 2024. The bacillus subtilis is bacillus subtilis which can produce surfactin well and has a strong inhibition effect on clostridium perfringens, and the bacillus subtilis also has a certain inhibition effect on large intestines, salmonella and staphylococcus aureus.

Portulaca oleracea fermentation process

Resumen de: CN120436313A

The invention provides a portulaca oleracea fermentation process, which utilizes lactobacillus plantarum BJ-M8 with carbohydrate amylase, glucosidase and cellulase production capacity to ferment portulaca oleracea, and promotes the conversion of macromolecular glycoside substances to small molecular aglycones. Metabonomics analysis shows that through fermentation treatment of the strain BJ-M8, the composition of alkaloids, phenolic acids, flavonoids and the like of purslane is effectively improved. Compared with the prior art, the target product calycosin is increased by 10 times, acacetin is increased by 7 times, kaempferol is increased by 4 times, apigenin is increased by 4 times, naringenin is increased by 3 times, dihydroferulic acid is increased by 177 times, dihydrocaffeic acid is increased by 27 times, and spinogenin is increased by 6 times. According to an in-vitro evaluation test, the inhibition effect of the fermented purslane on salmonella and escherichia coli is enhanced, the anti-inflammatory effect on LPS treated macrophage RAW264.7 and the oxidation resistance on Caco-2 cells are improved, and the application prospect in the aspect of functional product preparation is wide.

Bacteriophage capable of splitting salmonella bolidanae as well as composition and application of bacteriophage

Resumen de: CN120442560A

The invention relates to the technical field of salmonella bacteriophages, and in particular relates to a bacteriophage capable of splitting salmonella brassicae as well as a composition and application of the bacteriophage capable of splitting the salmonella brassicae. The bacteriophage is salmonella bacteriophage RDP-SA-22010, the preservation number of the bacteriophage is CGMCC (China General Microbiological Culture Collection Center) No.45274, and the bacteriophage is preserved in the China General Microbiological Culture Collection Center on September 21, 2022. The salmonella bacteriophage RDP-SA-22010 can also be used for cracking salmonella enteritidis, salmonella pullorum and salmonella kafenkii. The invention also relates to a composition, which comprises the salmonella bacteriophage RDP-SA-22010. The reagent or the kit comprises the composition. The invention also provides application of the salmonella bacteriophage RDP-SA-22010 to preparation of a biological bactericide, preparation of a medicine for treating diseases caused by salmonella and preparation of a feed additive. The salmonella bacteriophage RDP-SA-22010 disclosed by the invention provides a novel biological prevention and treatment means for the prevention and treatment of salmonella bulidan.

Cross-species lysis bacteriophage RDP-EC-20146 and application thereof

Resumen de: CN120442561A

The invention provides a cross-species lysis bacteriophage RDP-EC-20146 and application thereof, and belongs to the technical field of biology. The cross-species lysis bacteriophage is an escherichia coli bacteriophage, the preservation number is CGMCC (China General Microbiological Culture Collection Center) No.45351, and the cross-species lysis bacteriophage is preserved in China General Microbiological Culture Collection Center on October 28, 2022. The cross-species lysis bacteriophage RDP-EC-20146 provided by the invention has the characteristics of high lysis activity and good physical and chemical factor tolerance; the method is not influenced by the drug resistance of bacteria, does not have the problems of drug residues and the like, and has very high use safety; in addition, when the bacteriophage RDP-EC-20146 provided by the invention is combined with 8 low-dose antibiotics for use, a remarkable bacteriostatic effect can be shown, and the bacteriophage RDP-EC-20146 has a good application prospect in the aspect of preventing and treating salmonella, escherichia coli, staphylococcus aureus and/or pseudomonas aeruginosa diseases.

MICROBIOME ENGINEERING TO TREAT COLITIS

Resumen de: WO2025165867A1

Provided herein are compositions comprising in vivo succinate-producting microorganisms, e.g., Bacteroides and Prevotella species (preferably Bacteroides thetaiotaomicron (e.g., VPI 5482), Bacteroides vulgatus (e.g., NCTC 11154, Prevotella copri (e.g., DSM 18205)), Parabacteroides (e.g., Parabacteroides distasonis), and Bacilli (e.g. Lactobacillus animalis), and methods of use thereof in treating or reducing risk of developing an intestinal infection, optionally an infection with Campylobacter, Salmonella, E. coli, Shigella, Listeria monocytogenes, Vibrio, Enteropathogenic E. coli, Klebsiella, or Clostridioides difficile, or promoting expansion of colonic tuft cells, in a subject.

Colorimetric-fluorescence dual-signal salmonella detection method based on Ag-MoS2 nano-enzyme

Resumen de: CN120427903A

The invention discloses a colorimetric-fluorescent dual-signal salmonella detection method based on Ag-MoS2 nano-enzyme. The method is characterized by comprising the following steps: mixing a single strand S1, a single strand S2, a single strand S3, a single strand S4, a salmonella aptamer and cDNA (complementary deoxyribonucleic acid) to prepare a multivalent aptamer competitive probe solution; respectively dissolving a hairpin probe H1 and a hairpin probe H2 in PBS (Phosphate Buffer Solution); a step of preparing an Ag-MoS2 nano enzyme composite material; the method comprises the following steps: mixing and incubating a to-be-detected salmonella solution and a multivalent aptamer competitive probe, adding the Ag-MoS2 nano-enzyme composite material for performing CHA amplification reaction, then adding an H2O2 solution and a TMB solution for performing peroxidase catalytic reaction, respectively performing colorimetric method and fluorescence method detection, and calculating to obtain the salmonella concentration in the to-be-detected solution. The kit has the advantages of simplicity, rapidness, high sensitivity, strong specificity, high accuracy and real-time sterilization after detection.

COMPOSITION FOR DETECTING SALMONELLA AND DETECTION METHOD USING THE SAME

Resumen de: KR20250117498A

본 발명은 살모넬라 균 (Salmonella spp.) 검출용 조성물 및 이를 이용한 검출방법에 관한 것으로서, 보다 상세하게는 살모넬라 균 InvA 유전자 서열을 증폭하기 위한 프라이머 세트와 프로브에 관한 것으로, 식용 갈색거저리 내 유해균인 살모넬라 균을 특이적으로 검출 할 수 있다.

Florfenicol nano-liposome as well as preparation method and application thereof

Nº publicación: CN120420281A 05/08/2025

Solicitante:

ANHUI AGRICULTURAL UNIV
\u5B89\u5FBD\u519C\u4E1A\u5927\u5B66

Resumen de: CN120420281A

The invention discloses florfenicol nano-liposome and a preparation method and application thereof, the florfenicol nano-liposome is prepared from soybean lecithin, florfenicol and cholesterol according to the mass ratio of (10-30): 4: 5, florfenicol, cholesterol and soybean lecithin are dissolved in an organic solvent, rotary evaporation is performed, water is added for dissolution, and then ultrasonication is performed to obtain the florfenicol nano-liposome. The average particle size of the florfenicol liposome prepared by the preparation method disclosed by the invention is 249.6 to 638.2 nm, the Zeta potential value of the florfenicol liposome is-13.7 to-46.3 mV, and the polydispersity coefficient of the florfenicol liposome is 0.22 to 0.86. The entrapment rate is 88.31%-92.94%, the drug loading capacity is 3.21%-6.29%, the minimum inhibitory concentration to a salmonella standard strain is 4 mu g/mL, and the minimum bactericidal concentration to the salmonella standard strain is 8 mu g/mL. The minimum inhibitory concentration of the salmonella drug-resistant strain is 8 mu g/mL, and the minimum bactericidal concentration of the salmonella drug-resistant strain is 34 mu g/mL.